MN SF14

Allows payment for injectable drugs used to treat substance use disorder to be made to the administering facility, practitioner, administering pharmacy or pharmacist, or directly to the dispensing pharmacy, with claim submission requirements based on the source of drug purchase.

Prohibits pharmacies from dispensing practitioner-administered injectable drugs directly to enrollees.

Requires the commissioner to contract with a vendor to conduct a cost of dispensing survey for Minnesota pharmacies by January 1, 2021, and repeat every three years, with results reported to legislative committees.

Increases ingredient cost reimbursement by 1.8 percent for prescription and nonprescription drugs subject to the wholesale drug distributor tax.

Maintains existing professional dispensing fees of $10.48 for legend drugs and intravenous solutions, with lower fees for over-the-counter drugs and proration for partial package dispensing.